3-isobutyl-octanedioic acid | 100250-83-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-isobutyl-octanedioic acid
• 英文别名: 3-Isobutyl-octandisaeure；3-(2-Methylpropyl)octanedioic acid
• CAS: 100250-83-7
• 化学式: C₁₂H₂₂O₄
• 分子量: 230.304
• InChiKey: SPNRVDRQLSFBOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-isobutyl-adipic acid 在 氯化亚砜 、 乙醚 作用下， 生成 3-isobutyl-octanedioic acid
  参考文献：
  名称：

  314.Dioscorea hispida，dennstedt的一种生物碱。第三部分 霍夫曼降解的进一步研究

  摘要：

  DOI：

  10.1039/jr9560001577

文献信息

• Antibodies derived from anti ed-b l19 and targeting tumor vasculature
  申请人：Philogen S.p.A.

  公开号：EP2174958A1

  公开（公告）日：2010-04-14

  The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.

  本发明涉及使用人重组 scFv L19 选择性地靶向体内肿瘤血管，该 scFv 与纤维粘连蛋白的血管生成标志物 ED-B 结构域相关。在优选的实施方案中，采用的是具有 L19 可变区的完整人 IgG1。在其他实施方案中，采用的是通过将 scFv L19 与分泌型 IgE 异构体的恒定 CH4 结构域融合而产生的迷你免疫球蛋白，这种分泌型 IgE 异构体在其 COOH 末端天然含有半胱氨酸，并形成共价连接的二聚体。根据临床需要和疾病的不同，抗体格式的不同体内行为可用于不同的诊断和/或治疗目的。抗体分子可按描述进行标记。
• ANTIBODIES DERIVED FROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE
  申请人：Philogen S.p.A.

  公开号：EP1483297A2

  公开（公告）日：2004-12-08
• TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B
  申请人：Philogen S.p.A.

  公开号：EP1663320A1

  公开（公告）日：2006-06-07
• [EN] SELECTIVE TARGETING OF TUMOR VASCULATURE USING ANTIBODY MOLECULES<br/>[FR] CIBLAGE SELECTIF D'UN SYSTEME VASCULAIRE TUMORAL AU MOYEN DE MOLECULES D'ANTICORPS
  申请人：PHILOGEN SRL

  公开号：WO2003076469A2

  公开（公告）日：2003-09-18

  The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.
• [EN] ANTIBODIES DERIVED ROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE<br/>[FR] CIBLAGE SELECTIF D'UN SYSTEME VASCULAIRE TUMORAL AU MOYEN DE MOLECULES D'ANTICORPS
  申请人：——

  公开号：WO2003076469A9

  公开（公告）日：2005-09-29

  [EN] The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.
  [FR] La présente invention concerne le ciblage sélectif d'un système vasculaire tumoral in vivo au moyen d'un scFv recombinant, L19, sur le domaine ED-B du marqueur d'angiogenèse de la fibronectine. Dans des modes de réalisation préférés, on utilise une IgG1 humaine complète comprenant les régions variables de L19. Dans d'autres modes de réalisation, on utilise une mini-immunoglobuline produite par fusion du scFv L19 avec le domaine CH4 constant d'une isoforme d'IgE sécrétrice contenant naturellement une cystéine dans sa terminaison COOH et formant un dimère lié par covalence. On peut utiliser un comportement in vivo différent des formats d'anticorps à diverses fins diagnostiques et/ou thérapeutiques, selon les besoins cliniques et la maladie. Ces molécules d'anticorps peuvent être marquées comme indiqué dans la description.